Amitiza end-payors file reply for class certification in US antitrust case against Takeda
MLex Summary: End-payors for the drug Amitiza filed a reply in support of their request for class certification in litigation accusing Takeda Pharmaceuticals of delaying a generic competitor. If approved, the...To view the full article, register now.
Already a subscriber? Click here to view full article